TCF7L2 Antibody (SC06-90)

TCF7L2, or TCF4, is a high mobility group (HMG) box-containing transcription factor that plays a key role in the Wnt signaling pathway. TCF7L2 has been implicated in glucose homeostasis through the regulation of pro-glucagon gene expression, which encodes glucagon-like peptide 1 (GLP-1). Genetic variants of TCF7L2 have been linked to type 2 diabetes, and it has specifically been shown to have an important role in the regulation of both 946;-cell survival and function (4). Several splicing isoforms for TCF7L2 have been shown to be differentially expressed in tissues during cancer progression (3), and gene targeting studies indicate that TCF7L2 is required to maintain the crypt stem cells of the small intestine (1, 2).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Mouse.

We have publications tested in 1 application: IHC-P.

Showing Publication 1 - 1 of 1.

Publication using NBP2-67618	Applications	Species
Fan L, yang H, Hu X et al. ZD-2, a novel DPP4 inhibitor, protects islet beta-cell and improves glycemic control in high-fat-diet-induced obese mice Life Sciences 2022-06-01 [PMID: 35367243] (IHC-P, Mouse)	IHC-P	Mouse

Array NBP2-67618

• TCF7L2 Antibodies
• TCF7L2 Lysates
• TCF7L2 Proteins